盘龙药业2024年度业绩说明会成功举办 秦药智慧与前沿科技碰撞火花，特色产品集群初具规模

Core Viewpoint - The performance meeting of Panlong Pharmaceutical for the year 2024 highlighted the company's steady growth, innovative strategies, and commitment to social responsibility, with a focus on traditional Chinese medicine and modern pharmaceutical development [1][4][9]. Financial Performance - In 2024, Panlong Pharmaceutical achieved a revenue of 974 million yuan and a net profit attributable to shareholders of 120 million yuan, representing a year-on-year growth of 8.91% [7]. - The sales revenue of the leading products experienced double-digit growth, while the plant medicine sector saw a three-digit increase [7]. Product Development and Innovation - The company has made significant advancements in research and development, particularly in new traditional Chinese medicine, chemical drugs, and medical institution formulations [7]. - The self-developed innovative traditional Chinese medicine PLZY-001 is accelerating clinical exploration, and several chemical generic drugs have successfully completed pilot tests [7]. - The establishment of the Panlong Xinyuan (Guangdong) New Drug Research and Transformation Base in the Guangdong-Hong Kong-Macao Greater Bay Area aims to enhance innovation capabilities [7]. Strategic Vision and Future Plans - The company plans to increase cash dividends to shareholders, proposing a cash dividend of 31.77 million yuan, which accounts for 26.42% of net profit [9]. - The strategic vision includes becoming a leader in the field of wind and bone injury medications and a specialist in chronic pain management, with a focus on a comprehensive development strategy [9]. - The company aims to enhance its governance and operational efficiency through a specialized and compliant marketing organization and a robust research and development system [9][11].